Page last updated: 2024-09-05

erlotinib hydrochloride and Carcinoma, Bronchogenic

erlotinib hydrochloride has been researched along with Carcinoma, Bronchogenic in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Braiteh, F; Johnson, FM; Kurzrock, R	1
Bago-Horvath, Z; Berger, W; Filipits, M; Grusch, M; Haitel, A; Hayden, H; Komina, O; Lackner, A; Pirker, C; Schmid, K; Sieghart, W; Węsierska-Gądek, J	1
Blackhall, F; Danson, S; Papakotoulas, PI; Thatcher, N	1

Reviews

1 review(s) available for erlotinib hydrochloride and Carcinoma, Bronchogenic

Article	Year
Perspectives on novel therapies for bronchial carcinoma. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Vascular Endothelial Growth Factor A	2005

Article

Year

Perspectives on novel therapies for bronchial carcinoma.

Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Vascular Endothelial Growth Factor A

2005

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Carcinoma, Bronchogenic

Article	Year
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Brain Neoplasms; Carcinoma, Bronchogenic; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Risk Assessment	2008
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. Neuroendocrinology, 2012, Volume: 96, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Child; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Young Adult	2012

Article

Year

Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20

Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Brain Neoplasms; Carcinoma, Bronchogenic; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Risk Assessment

2008

Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.

Neuroendocrinology, 2012, Volume: 96, Issue:3

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Child; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Young Adult

2012